B-Type Natriuretic Peptide as Biomarker of COVID-19 Disease Severity—A Meta-Analysis
Abstract
:1. Introduction
2. Experimental Section
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Guo, T.; Fan, Y.; Chen, M.; Wu, X.; Zhang, L.; He, T.; Wang, H.; Wan, J.; Wang, X.; Lu, Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020, 5, 811–818. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lai, C.-C.; Sung, M.-I.; Ho, C.-H.; Liu, H.-H.; Chen, C.-M.; Chiang, S.-R.; Chao, C.-M.; Liu, W.-L.; Hsing, S.-C.; Cheng, K.-C. The prognostic value of N-terminal proB-type natriuretic peptide in patients with acute respiratory distress syndrome. Sci. Rep. 2017, 7, 44784. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mitaka, C.; Hirata, Y.; Nagura, T.; Tsunoda, Y.; Itoh, M.; Amaha, K. Increased plasma concentrations of brain natriuretic peptide in patients with acute lung injury. J. Crit. Care 1997, 12, 66–71. [Google Scholar] [CrossRef]
- Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020, 5, 802–810. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jannuzzi, J. Troponin and BNP Use in COVID-19. Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 (accessed on 21 July 2020).
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int. J. Surg. 2010, 8, 336–341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, G.; Zhao, H.; Fei, Y.; Shen, A.; Chen, H.; Li, H. Autoimmune Diseases May Increase Adverse Cardiovascular Events After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2019, 28, 1510–1524. [Google Scholar] [CrossRef] [PubMed]
- Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014, 14, 135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sorrentino, S.; Nguyen, P.; Salerno, N.; Polimeni, A.; Sabatino, J.; Makris, A.; Hennessy, A.; Giustino, G.; Spaccarotella, C.; Mongiardo, A.; et al. Standard Versus Ultrasound-Guided Cannulation of the Femoral Artery in Patients Undergoing Invasive Procedures: A Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2020, 9, 677. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weber, M.; Hamm, C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2005, 92, 843–849. [Google Scholar] [CrossRef] [PubMed]
- Indolfi, C.; Piscione, F.; Volpe, M.; Focaccio, A.; Lembo, G.; Trimarco, B.; Condorelli, M.; Chiariello, M. Cardiac effects of atrial natriuretic peptide in subjects with normal left ventricular function. Am. J. Cardiol. 1989, 63, 353–357. [Google Scholar] [CrossRef]
- Thomas-Rüddel, D.; Winning, J.; Dickmann, P.; Ouart, D.; Kortgen, A.; Janssens, U.; Bauer, M. Coronavirus disease 2019 (COVID-19): Update for anesthesiologists and intensivists March 2020. Der Anaesthesist 2020, 69, 225–235. [Google Scholar] [CrossRef] [Green Version]
Chen C. et al. | Chen T. et al. | Deng P. et al. | Deng Q. et al. | Han H. et al. | Li K. et al. | Lu Z. et al. | |
Journal | JCMA | BMJ | CCA | IJC | JMV | MedRxiv | Lancet |
Study Design | Retrospective, multicenter, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry |
Enrollment Period | January–February 2020 | 13 January–12 February 2020 | January–February 2020 | 6 January–20 February 2020 | 1 January–18 February 2020 | 31 January–5 March 2020 | January–February 2020 |
Groups definition | Severe vs. non-severe | Non-Survivors vs. survivors | Non-Survivors vs. survivors | Severe vs. non-severe | Severe vs. non-severe | Non-Survivors vs. survivors | Non-Survivors vs. survivors |
Death or Severe group | 24 | 113 | 52 | 67 | 60 | 15 | 31 |
Age | 68.5 (13.6) | 68.0 (62.0–77.0) | 74.5 (65.3–81.8) | 68.0 (57.0–77.0) | 59.1 (14.4) | 69.0 (58.0–77.0) | 72.0 (9.0) |
Female (%) | 6 (25.0%) | 30 (26.6%) | 19 (36.5%) | 29 (43.3%) | 39 (65.0%) | 4 (27.0%) | 9 (29.1%) |
Days from symptom onset to hospital admission | NA | 10 (7–13) | NA | NA | NA | 9 (6–14) | 22.1 (17.0–28.0) |
NT pro BNP (pg/mL) | 1030.0 (339.0–2276.0) | 800.0 (389.8–1817.5) | 943.2 (402.3–2.397,5) | 1142.0 (388.3–5956.5) | 290.9 (106.1–958.1) | 817.5 (348.5–3031.0) | 4868.0 (8839.0) |
EF (%) | NA | NA | NA | 58.5 ± 5.4 | NA | NA | NA |
Non-severe group | 126 | 161 | 212 | 45 | 198 | 87 | 92 |
Age | 57.1 (15.6) | 51.0 (37.0–66.0) | 62.5 (52.0–70.0) | 56.0 (39.0–67.0) | 59.0 (10.8) | 55.0 (44.0–66.0) | 53.0 (14.0) |
Female (%) | 60 (47.6%) | 73 (45.4%) | 115 (54.2%) | 26 (57.8%) | 127 (64.2%) | 39 (44.8%) | 53 (57.6%) |
Days from symptom onset to hospital admission | NA | 9.0 (6.0–12.0) | NA | NA | NA | 11.0 (8.0–18.0) | 17.7 (13.0–23.0) |
NT pro BNP (pg/mL) | 83.0 (28.0–232.0) | 72.0 (20.0–185.0) | 155.0 (64.4–460.3) | 101.9 (34.0–363.8) | 113.7 (45.9–274.2) | 92.5 (42.3–266.5) | 283.4 (229.1) |
EF (%) | NA | NA | NA | 62.0 ± 5.5 | NA | NA | NA |
Nguyen A.B. et al. | Rath D. et al. | Yun L. et al. | Zhu Z. | Zheng X. et al. | Zheng Y. et al. | ||
Journal | MedRxiv | CRIC | CJID | IJID | Lancet | JCV | |
Study Design | observational single center, single arm registry | prospective, single center, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry | Retrospective, single center, single arm registry | |
Enrollment Period | 16 March–16 April 2020 | 1 February–31 March 2020 | 20 January–10 February 2020 | 23 January–20 February 2020 | January–March 2020 | 16 January–20 February 2020 | |
Groups definition | Non-Survivors vs. survivors | Non-Survivors vs. survivors | Severe vs. non-severe | Severe vs. non-severe | Severe vs. non-severe | Critical vs. non critical | |
Severe group | 45 | 16 | 21 | 16 | 22 | 32 | |
Age | 72.0 (61.0–81.0) | 73.0 (16.0) | 65.5 (15.7) | 57.5 (11.70) | 58.2 (13.2) | 63.8 (16.5) | |
Female (%) | 20 (44.4%) | 4 (25.0%) | 2 (9.5%) | 7 (43.8%) | 11 (50.0%) | NA | |
Days from symptom onset to hospital admission | NA | NA | 5 (3–7) | 6.9±2.8 | 4.6 ± 3.7 | NA | |
NT pro BNP (pg/mL) | 407.0 (109–1.779) | 1992.0 (416–7719) | 95.1 (39.2–601.2) | 196.5 (75.9–405.1) | 180.2 (209.8) | 1085.5 (3217.1) | |
EF (%) | NA | 49.0 (12.1) | NA | NA | NA | NA | |
Non-severe group | 308 | 107 | 271 | 111 | 30 | 67 | |
Age | 60.0 (48.5–71.5) | 67.0 (15.0) | 48.7 (15.7) | 50.0 (15.5) | 45.6 (16.0) | 42.5 (15.1) | |
Female (%) | 164 (53.2%) | 42 (39.3%) | 136 (50.2%) | 38 (34.2%) | 18 (60%) | NA | |
Days from symptom onset to hospital admission | NA | NA | 4.0 (2.0–7.0) | 5.1 (3.8) | 5.7 (6.0) | NA | |
NT pro BNP (pg/mL) | 112.0 (29.0–658.0) | 377 (132.0–1914.0) | 34.7 (23.3–65.1) | 118.0 (78.4–218.8) | 113.5 (186.0) | 66.9 (90.9) | |
EF (%) | NA | 58.0 ± 6.0 | NA | NA | NA | NA |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sorrentino, S.; Cacia, M.; Leo, I.; Polimeni, A.; Sabatino, J.; Spaccarotella, C.A.M.; Mongiardo, A.; De Rosa, S.; Indolfi, C. B-Type Natriuretic Peptide as Biomarker of COVID-19 Disease Severity—A Meta-Analysis. J. Clin. Med. 2020, 9, 2957. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9092957
Sorrentino S, Cacia M, Leo I, Polimeni A, Sabatino J, Spaccarotella CAM, Mongiardo A, De Rosa S, Indolfi C. B-Type Natriuretic Peptide as Biomarker of COVID-19 Disease Severity—A Meta-Analysis. Journal of Clinical Medicine. 2020; 9(9):2957. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9092957
Chicago/Turabian StyleSorrentino, Sabato, Michele Cacia, Isabella Leo, Alberto Polimeni, Jolanda Sabatino, Carmen Anna Maria Spaccarotella, Annalisa Mongiardo, Salvatore De Rosa, and Ciro Indolfi. 2020. "B-Type Natriuretic Peptide as Biomarker of COVID-19 Disease Severity—A Meta-Analysis" Journal of Clinical Medicine 9, no. 9: 2957. https://0-doi-org.brum.beds.ac.uk/10.3390/jcm9092957